Background
==========

Cancer is a heterogeneous disease with multiple genetic events and subsequent clonal evolution, which potentially generate numerous tumor neoantigens monitored by the immune system, which activate antitumor immune response to eradicate or control tumor growth, which is the essence of cancer immunosurveillance [@B1]-[@B3]. On the other hand, tumors also develop multiple strategies to avoid immune attack and even actively suppress immune system. One aspect of the immunoediting hypothesis is that tumors can evade immune surveillance by expressing molecules inhibiting the anti-tumor immune response, including immuno-suppressive cytokines such as IL‑10 (Interleukin-10) [@B4], transforming growth factor-β (TGF-β)[@B5], and immune co-inhibitory signaling proteins such as Programmed cell death protein 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) [@B6], etc. The discovery of the co-inhibitory pathways boost the antibody blockade therapeutics targeting these molecules, such as anti-PD-1, anti-PD-L1 and anti-CTLA4 [@B7], [@B8]. Up to now, these therapies have achieved noteworthy efficacy in multiple types of cancers by blocking cancer immune evasion and enabling patients to reinvigorate an effective anti-cancer response[@B8]-[@B13]. Nevertheless, the efficacy of checkpoint blockade antibodies was far from satisfying in CRC patients [@B13], [@B14].

Previously, tumors with a high burden of neoantigens and low intratumor heterogeneity were found to be significantly more responding to immunotherapy [@B15]. Recently, several studies reported that mismatch repair (MMR) gene MSH2, MSH6,MLH1 and PMS2 are involved in DNA repair and loss of the proteins can result in frameshift mutations and potentially cause high neoantigen burden[@B1], [@B16], [@B17]. Accordingly, tumors with MMR-deficiency (dMMR) may have a relatively high neoantigen spectrum, which subsequently induce T lymphocytes infiltration and anti-tumor immune response, and form totally different tumor immune microenvironment (TME) from that of MMR-proficient (pMMR) tumors. A recent clinical trial suggested that only the CRC patients with dMMR derived clinical benefit from anti-PD-1 therapy[@B14]. The rationale is that dMMR CRC has higher mutation rate and potentially generate more neoantigens, which serve as targets for anti-tumor immunity recovered by PD-1 blockade. Nevertheless, the exact mechanisms underlying such superior efficacy in this specific subtype of CRC patients are still not completely clear. Furthermore, the prognostic value of PD-1/PD-L1 expression and the systemic inflammatory response markers for dMMR CRC patients has not been fully investigated. Therefore, we designed a study to identify the difference of systemic and local inflammation-related, PD-1/PD-L1 pathway-related TME between dMMR and pMMR CRC, and to explore potential prognosis prediction markers for CRC immunotherapy.

Materials and Methods
=====================

Study design and participants
-----------------------------

A single center study was conducted at the Sun Yat-sen University Cancer Center (SYSUCC), and the database of our institution contains more than 4000 CRC patients who were admitted between January 2003 and October 2015. This study was approved by SYSUCC institutional review board, and all the participants signed informed consent forms. Among these patients, a total of 2,901 CRC patients underwent MSI testing from May 2011 to Jane 2015, and 244 (8.4%) were with dMMR status. In addition, we excluded patients with following criteria: cancer other than CRC, stage unknown, and vital status unknown or lost to follow-up. Next, we identified another 169 patients of pMMR status matched with the dMMR patients in clinicopathological characteristics (**Figure [1](#F1){ref-type="fig"}**). Characteristics of pMMR patients enrolled and total were compared using multivariable analysis (**Table [S1](#SM0){ref-type="supplementary-material"}**).

All enrolled patients were confirmed the diagnosis of CRC and the pathological type by pre-therapy pathologic examination. Age, sex, tumor location, tumor grade, histological subtype, tumor stage, regional lymph nodes (LNs) metastasis, distant metastasis, American Joint Committee on Cancer (AJCC) 7th edition staging, perineural invasion, vascular invasion, number of retrieved LNs, chemotherapy status, radiotherapy status, serum inflammatory factors, and serum tumor markers, such as carcinoembryonic antigen (CEA) (upper physiological value: 5 ng/ml) and carbohydrate antigen 19-9 (CA19-9) (upper physiological value: 30 U/ml) were retrospectively reviewed. Follow-up examinations including computed tomography (CT) scans were conducted regularly. Furthermore, we routinely obtained the follow-up data from the institutional database, which was constantly updated based on physician records, tumor registry information, and telephone interviews.

Immunohistochemical analysis of MMR proteins, PD-1, and PD-L1 expression
------------------------------------------------------------------------

For immunohistochemical (IHC) staining of markers in the tumor tissues, 4 μm-thick unstained histological sections from each formalin-fixed, paraffin-embedded tissue block were de-waxed with xylene and rehydrated in 100%, 95%, and 70% ethanol to water. Analysis for MMR-related proteins was conducted as previously described [@B18]. For antigen retrieval, the slides were dipped in EDTA (PH=8.0) and heated in an autoclave for 10 minutes. Endogenous peroxidase activity was quenched through incubation with 3% H~2~O~2~ for 10 minutes. Slides were incubated at 37°C for 50 minutes with diluted monoclonal antibodies (dilution 1:50) as follows: anti-hMLH1 (ZSGB-BIO Corp, ZM-0154, Beijing, China), anti-hMSH2 (ZSGB-BIO Corp, ZA-0622, Beijing, China), anti-hMSH6 (ZSGB-BIO Corp, ZA-0541, Beijing, China), and anti-hPMS2 (ZSGB-BIO Corp, ZA-0542, Beijing, China) antibodies. Slides were then processed using a DAB Detection kit (ZSGB-BIO Corp, PV-6000-D, Beijing, China) according to the manufacturer\'s instructions. Finally, the sections were incubated with diaminobenzidine, counterstained with haematoxylin, dehydrated in ascending graded of ethanol and mounted. In accordance with previous studies, the immunostaining was classified into two grades for MMR proteins (-, ≤10%; +, \>10% nuclear staining) (**Figure [S1](#SM0){ref-type="supplementary-material"}**) [@B19], [@B20].

IHC staining for PD-1 and PD-L1 expression was performed as described in previous study [@B21], [@B22]. The primary antibodies were used as follows: anti-PD-1 (CST Corp, \#10084, Massachusetts, USA), anti-PD-L1 (CST Corp, \#10084, Massachusetts, USA), and DAKO Envision kit (DAKO Corp, Carpinteria, CA, USA). In addition, PD-1 and PD-L1 immunostaining was divided into two groups based on intensity and extent (-,≤5%; +,\>5%, membranous staining) (0,≤5%; 1, 6% to 25%; 2, 26% to 50%; 3, 51% to 75%; 4, \>75%) (**Figure [S2](#SM0){ref-type="supplementary-material"}**).[@B23]

Tumor infiltrating lymphocytes evaluation
-----------------------------------------

Tumor-infiltrating lymphocytes (TILs) was assessed in HE-stained sections as previously reported [@B24]. Only small blue mononuclear cells that typically had a halo around tumor cells were counted. Samples were analyzed according to the mean TIL/high-powered field (HPF) calculated for each tumor. The cutoff value of mean TIL number/HPF was determined using receiver operating characteristic (ROC) curve analyses. Tumors were then divided into two groups (TIL/HPF≥2 or TIL/HPF\<2) according to the cutoff value. The expression of PD1 and PD-L1 in TILs was estimated using IHC method mentioned above.

Definition of inflammation-based prognostic score
-------------------------------------------------

Based on a previous study, the Glasgow Prognostic Score (GPS) was calculated as follows: patients with elevated levels of both C-reactive protein (CRP) (\>10 mg/dl) and hypo-albuminemia (\<3.5 g/dl) were allocated a score of 2, and patients showing only one or none of these blood chemistry abnormalities were allocated a score of 1 or 0, respectively. The NLR was calculated as: NLR= neutrophil ratio (%) (or number of neutrophils)/ Lymphocyte ratio (%) (or number of lymphocytes). The CAR was calculated as: CAR = serum CRP level (mg/dl)/serum albumin level (g/dl)[@B25].

Statistical analysis
--------------------

All the statistical analysis was conducted with SPSS software (Version 19.0, SPSS). Patients\' clinicopathological characteristics and the associations between PD-L1and MMR markers expression were evaluated using the Fisher\'s exact test or the χ^2^ tests. The primary endpoints --- overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method, and survival curves were compared using the log-rank test method. The Cox-regression analysis, both univariate and multivariate, was performed to identify the independency of prognostic factors status. Hazard ratios (HR) and 95% confidence intervals (CIs) were used to determine the prognostic impact of factors on survival time for univariate models, or multivariate models adjusted for variants including MMR status, age, gender, tumor location, tumor grade, histological subtype, LNs metastasis, distant metastasis, perineural invasion, vascular invasion, number of retrieved LNs, therapy status (chemotherapy and radiotherapy), and AJCC staging. All tests were two-sided, and a *P* value \<0.05 was considered to be statistically significant.

Results
=======

Baseline patient characteristics
--------------------------------

The patient selection is presented in **Figure [1](#F1){ref-type="fig"}** (and detailed in the Methods section). Comparison of clinicopathological characteristics between dMMR and pMMR CRC patients was listed in **Table [1](#T1){ref-type="table"}**. Of the 337 CRC patients, 169 (50.1%) of the patients were pMMR and 168(49.9%) were dMMR. Patients with dMMR presented at a younger age (53.5 v 58.5 years, *P*\<0.001), and were more frequently found on right hemicolon for tumor location (46.4% v 27.8%, *P*=0.001) and grade 3 (46.4% v 26.0%, *P*\<0.001) for tumor grade, and more with mucinous histological subtype (35.7% v 17.8%, *P*\<0.001). In addition, a significant lower proportion of dMMR patients were with advanced tumor stage. There was no significant difference between the two groups in gender, regional LNs metastasis, distant metastasis, AJCC stage, perineural invasion, vascular invasion, number of retrieved LNs, chemotherapy, and radiotherapy treatment.

Serum tumor markers and systemic inflammatory markers
-----------------------------------------------------

CRC patients with pMMR were more likely to present a high level of circulating serum CEA (46.2% v 35.1%, *P*=0.046) (**Table [2](#T2){ref-type="table"}**). In addition, there was significant difference between the two groups in systemic inflammatory makers including C-reactive protein (\<8.2/≥8.2)(mg/L), NLR (\<1.8/≥1.8), and GPS (0/1/2).Specifically, a larger proportion of dMMR group showed high level of C-reactive protein (38.7% v 17.2%, *P*\<0.001), high level of NLR (80.4% v 68.6%, *P*=0.017), and GPS (core 1, 30.4% v 14.2%, *P*\<0.001). The circulating lymphocytes level was not associated with MMR status, and showed a decreasing trend in stage 4 CRC patients; By contrast, NLR levels significantly increased in stage 4 patients (**Figure [2](#F2){ref-type="fig"}B-F**). Similarly, several other inflammatory factors like CRP, CAR, and GPS, significantly increased in late stage pMMR group, and exhibited an increasing tendency in late stage dMMR patients (**Figure [S3](#SM0){ref-type="supplementary-material"}**).

PD-1/PD-L1 axis in dMMR and pMMR CRC patients
---------------------------------------------

All PD-1/PD-L1 pathway results between two cohorts are shown in **Figure [3](#F3){ref-type="fig"}** and **Table [3](#T3){ref-type="table"}**. Total PD-1 and PD-L1 positive expression rate were 60.5% (204/337) and 51.9% (175/337), respectively. When stratified with MMR status, positive staining ratio of total PD-1 (62.5% v 58.6%, *P*=0.504) and PD-L1 (55.4% v 48.5%, *P*=0.231) was similar between two groups. We analyzed the distribution pattern of PD-1 and PD-L1 staining on different areas (total, tumor, TIL, and stroma) (**Figure [3](#F3){ref-type="fig"}A-B**), and the patterns of PD-1 and PD-L1 staining were also very similar in the two CRC groups. Among the various PD-1/PD-L1 expression patterns, dMMR patients showed higher TIL PD-1 (54.8% v 43.2%, *P*=0.039) and lower stroma PD-L1 (non-TIL and non-tumor) expression (22.0% v 43.8%, *P*\<0.001). Importantly, late stage dMMR patients, but not pMMR patients, showed significantly lower level of TIL PD-L1 or stroma PD-L1 (**Figure [3](#F3){ref-type="fig"}C-F**). Besides, MMR status is not associated with PD-1/PD-L1 staining patterns on different areas (**Table [3](#T3){ref-type="table"}**).

Prognostic factors in dMMR and pMMR CRC patients
------------------------------------------------

Overall survival (OS) and disease-free survival (DFS) curves are displayed in**Figure [4](#F4){ref-type="fig"}**. OS and DFS between the dMMR and pMMR groups were not significantly different. Interestingly, low level of circulating lymphocytes (\<1.12×10^9^/L), is associated with short OS (*P*=0.022) and short DFS (*P*=0.002) only in dMMR CRC, but not in pMMR CRC patients (**Figure [4](#F4){ref-type="fig"}A-D**). Consistently, circulating lymphocyte levels is lower in dMMR patients with short DFS when stratified with different DFS (\> 3 years and \<3 years) (**Figure [4](#F4){ref-type="fig"}E -F**).

Next, to determine whether the parameters examined above have other prognostic relevance, we conducted univariate and multivariate analysis in our patients (**Table [4](#T4){ref-type="table"}-[5](#T5){ref-type="table"}**). At the end of follow-up, 13 patients (7.7%) died in the dMMR cohorts and 9 patients (5.3%) died in the pMMR cohorts. In addition, 27 patients (16.1%) relapsed in the dMMR cohorts and 14 patients (8.3%) relapsed in the pMMR cohorts. OS and DFS between the dMMR and pMMR groups were not significantly different. The multivariate analyses results indicated that factors associated with decreased OS included distant metastasis(multivariable Cox HR, 5.23; 95% CI, 1.54 to 17.83; *P*=0.008), advanced AJCC stage (multivariable Cox HR, 7.35; 95% CI, 1.01 to 53.69; *P*=0.049), vascular invasion(multivariable Cox HR, 4.98; 95% CI, 1.63 to 15.24; *P*=0.005), radiotherapy (multivariable Cox HR, 4.40; 95% CI, 1.49 to 12.93; *P*=0.006), and low lymphocytes level (\<1.12×109/L) (multivariable Cox HR, 4.82; 95% CI, 1.12 to 20.69; *P*=0.035) (**Table [4](#T4){ref-type="table"}**). On the other hand, factors correlated with short DFS include distant metastasis (multivariable Cox HR, 4.39; 95% CI, 1.58 to 12.21; *P*=0.005), number of retrieved LNs (\<12) (multivariable Cox HR, 2.01; 95% CI, 1.00 to 4.03; *P*=0.049), and radiotherapy (multivariable Cox HR, 6.80; 95% CI, 2.86 to 16.17; *P*\<0.001) (**Table [5](#T5){ref-type="table"}**). Multivariate analysis after adjustment identified that the two groups have similar independent prognostic factors for OS and DFS (**Table [S2](#SM0){ref-type="supplementary-material"}-5**).

PD-L1 expression at different location has different impact on survival of CRC patients
---------------------------------------------------------------------------------------

Our initial results suggested that total PD-1 expression was not a prognostic marker, but the total PD-L1 expression was a good prognostic marker (**Figure [S4](#SM0){ref-type="supplementary-material"}**). When stratified with PD-L1 expression pattern, OS is not associated with either tumor PD-L1 expression (*P* = 0.838) (**Figure [5](#F5){ref-type="fig"}A**) or stroma PD-L1 expression (*P* = 0.356) (**Figure [5](#F5){ref-type="fig"}B**). Strikingly, high TIL PD-L1 expression significantly correlated with long OS and DFS of CRC patients (*P* = 0.019 for OS, *P*=0.030 for DFS), while PD-L1 expression in other areas has no association with survival (**Figure [5](#F5){ref-type="fig"}C-F**). By contrast, either total or localized PD-1 expression pattern was not associated with survival at all (**Figure [S5](#SM0){ref-type="supplementary-material"}**).

Discussion
==========

The current study comprehensively explored systemic inflammatory responses and PD-1/PD-L1 pathway-related tumor immune microenvironment between dMMR and pMMR CRC, and evaluated the potential of these features as prognostic factors for CRC. We found that different MSI status was associated with different systemic inflammatory responses and PD-L1/PD-L1 pathway-related TME in CRC. Furthermore, our study suggested PD-L1 expression on TIL was associated with OS and DFS of CRC patients.

A high level of systemic inflammation status and tumor immune cell infiltrates has previously been described with dMMR CRC patients [@B26]-[@B28]. For example, the inflammatory reaction markers such as GPS and NPS is significantly different in MSI vs MSS colorectal tumors[@B26]. Consistently, we also observed elevated levels of serum CRP, NLR, and GPS (Score 1) in dMMR group. It is also reported that NLR predicts DFS and OS and is associated with a more aggressive tumor phenotype, and the lymphocytic response to tumor at the invasive margin (IM) is associated with NLR [@B27]. However, NLR was not associated with prognosis in our study, and we only observed that the circulating serum lymphocytes could predict OS in CRC patients (**Table [4](#T4){ref-type="table"}**), and participants of advanced AJCC stage with relative low level in dMMR cohorts (**Figure [2](#F2){ref-type="fig"}B**). The systemic inflammation is generally associated with poor prognosis, emanating from inhibitory immune reaction along tumor progression. Whilst lymphocytes are often representing adaptive immune response controlling tumor. Our findings are concordant with such concept. The difference of DFS did not reach significance between two serum lymphocytes groups might be due to limited period of follow-up information collection. Interestingly, the prognosis of low level of circulating lymphocytes predicts short OS and DFS in dMMR CRC group, but not in pMMR group (**Figure [4](#F4){ref-type="fig"}**). This might imply that adaptive immune control of cancer is more prominent in dMMR CRC, of which loss of such control has a significant impact.

It is not unexpected to find the significant difference of PD-L1/PD-L1 expression patterns in dMMR and pMMR CRC patients. First, our study clearly showed that, despite similar distribution of PD-1 and PD-L1 in different area, PD-L1 expression on TIL and stroma (non-TIL and non-tumor) was significantly different between dMMR and pMMR CRC (**Figure [3](#F3){ref-type="fig"}A-B**). This is consistent with previous report that PD-L1 expression was largely on TILs but not tumor cells in dMMR CRC tumors [@B29]. Second, our study indicated that a potential inverse correlation between TIL PD-L1 or stroma PD-L1 and AJCC stage in dMMR patients (**Figure [3](#F3){ref-type="fig"}C-F**). We speculate the conspicuous drop of PD-L1 in AJCC stage 4 patients with concurrent decreased lymphocyte level may indicate a undermined antitumor immunity in late stage patients, and PD-1/PD-L1 pathway may weigh less in tumor immunity these patients. One recent report found that TIL PD-1 is an independent prognostic factor for OS and DFS of pMMR CRC patients, but not dMMR [@B30]. The authors suggested that TIL-PD1 might be associated with the regulatory and immune-suppressive T cells within colon microenvironment during an enhanced antitumor immune response. However, tumor PD-L1 expression was found inversely associated with FOXP3+ cell density in CRCs [@B31], which further confound the implications of such findings. By contrast, we only found higher expressions of total PD-L1 and TIL PD-L1 expression correlates with better OS and DFS of CRC patients but none serves as an independent prognostic factor for prognosis. Several potential reasons might explain the different result of our study. Firstly, we noticed that the studies used antibodies from different vendors, and the results were obtained from both TCGA database and tissue microarray [@B31], [@B32]. The technical variations in tissue staining could introduce some difference. Secondly, our data are obtained from cancer registries from a single center, which may introduce some degree of selection bias. Thirdly, our results of distribution analysis also displayed that, compared to pMMR cohorts, expression of total PD-L1decreased sharply in the AJCC stage 4, which implied that the importance of PD-1/PD-L1 in anti-tumor immunity might vary in different AJCC stages.

One important finding of our study is that the PD-L1 expression at different location has different impact on survival in CRC patients. PD-L1 is usually expressed by T and B cells, macrophages, dendritic cells (DC) and other normal cells [@B33]. PD-L1 is also expressed in many cancers, and is strongly associated with poor prognosis[@B34]-[@B37]. Furthermore, the expression of PD-L1 in tumor cells (TCs) has been identified as a predictive factor for tumor response to anti-PD-1 or anti-PD-L1 immunotherapy in various malignancies[@B13], [@B38]-[@B40]. For CRC, it was reported that patients with higher expression of PD-L1 had a poorer prognosis in colorectal serrated adenocarcinoma[@B41], in which PD-L1 could be one strategy for tumors to evade from immune attack. On the other hand, PD-L1 induction in colorectal cancer cells are blunted comparing to melanoma cells, while TILs and myeloid cells seemed more amenable to IFNγ-induced PD-L1 expression in colorectal tumors [@B29]. Thus, PD-L1 expression on TILs maybe a reflection of effector T cell activity. Consistently, several recent studies suggested PD-L1 expression is paradoxically associated with favorable survival in CRC, especially the TIL PD-L1[@B21], [@B30]. In a recent report, careful examination of localized PD1 and PD-L1 in CRC tumors suggested that high PD-1-positve TILs is associated with improved survival only when tumors have low level PD-L1 expression, and both high PD-1 positive TILs and high PD-L1 expression predicts worse recurrence free survival [@B42]. In our study, we found that total PD-1 was not a prognostic marker, but the total PD-L1 was a good prognostic marker in our cohorts, and high TIL PD-L1 expression significantly predicts a favorable prognosis in CRC patients (**Figure [5](#F5){ref-type="fig"}C**). Our result further supported the idea that PD-L1 on TIL may likely reflect the intratumor effector T cell activation, a major mechanism by which adaptive immune system controlling tumor. Lastly, our outcomes manifested that different area of PD-L1 with different impact on DFS in CRC and high TIL PD-L1 expression was significantly associated with long DFS in CRC (P=0.030) (**Figure [5](#F5){ref-type="fig"}**). Nevertheless, as the potential limitation of statistic power, the multivariate analysis results indicated total PD-PD-L1 and TIL PD-L1 were not the independent prognostic factor for survival. Hence, our study first demonstrated that, unlike previous studies, PD-L1 expression on specific area such like TIL PD-L1 might be a good predictor for prognosis in CRC.

To date there is no reliable prediction markers for patient response to PD-1 blockade. Although CD8 T cell infiltrates and intra-tumor PD-L1 expression was considered one of the most prominent features of responders, more in-depth analyses suggested localized PD-L1 expression on TILs and PD-L1/PD-1 proximity were more accurate in predicting melanoma patient response [@B38], [@B43]. TME in dMMR CRC patients was featured with abundant TIL infiltrates and elevated levels of multiple inhibitory molecules such as PD-1, PD-L1, LAG3, IDO-1, etc. which serve as a good target for PD-1 blockade [@B29]. Indeed, clinical trial result confirmed the hypersensitivity of these patients to anti-PD1 treatment. However, the response rate was still limited (4 out of 10 patients), and the histology data about intra-tumor PD-L1 expression was not clear [@B14]. Therefore, the value of intratumor PD-L1 expression in predicting response to PD-1 blockade warrant further investigation from clinical trials on more dMMR CRC patients. In addition, the systemic immune status pre-treatment may predict anti-PD1 response, as suggested by recent reports that high levels of circulating MDSCs or Ki67+PD1+ CD8 T cells is associated with unfavorable or favorable response to immunotherapy. Whether such association also exist in CRC patients remains to be investigated.

Despite our study\'s trustworthy strengths, including a large sample size, reliable follow-up information, primary tumor tissue slides, and full-scale molecular characterization, there are several limitations. Firstly, the main limitation is no consistent and accurate criteria for PD-L1 and TIL positive diagnosis. Although we diagnose these markers strictly based on previous established criteria and try our best to minimize diagnostic related error, we cannot guarantee absolute accurate diagnosis [@B23], [@B30], [@B44]. Secondly, our sample data are not derived from an RCT, and the data are limited by non-uniform of patient treatment and follow-up for events, and we did not analyze detailed treatment patterns or all classical features that have previously been noted as potential prognostic factors. Thirdly, we were not able to include any patients with PD-1/PD-L1 blockade therapy, leaving the prediction value of intratumor PD-L1 expression uncertain at this moment.

Overall, our study indicated a distinct TME characteristics is associated with dMMR CRC at specific disease stages, and that the PD-L1 expression on TIL may have a positive impact on survival of CRC patient, and worth future study for its prediction value for choosing right patients for PD-1/PD-L1 blockade therapy.
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![Different inflammatory status between dMMR and pMMR CRC patients. (a). The level of circulating lymphocytes in dMMR and pMMR CRC patients. (b-c). Group comparison combined the level of circulating lymphocytes and AJCC stages in dMMR patients (b) or pMMR patients (c). (d). The level of neutrophil to lymphocyte ratio (NLR) in dMMR and pMMR CRC patients. (e-f). Group comparison combined the level of NLR and AJCC stages in dMMR patients (e) or pMMR patients (f). \* *P*\<0.05, N.S, not significant.](jcav10p1745g002){#F2}

![PD-1/PD-L1 expression pattern between dMMR and pMMR CRC patients. (a-b). Distribution of PD-1 (a) or PD-L1 (b) expression for dMMR cohorts (n=168) versus pMMR cohorts (n=169) in CRC patients. (c-d). Group comparison combined the level of TIL PD-L1 and AJCC stages in dMMR (c) or pMMR patients (d). (e-f). Group comparison combined the level of stroma PD-L1 (non-TIL and non-tumor) and AJCC stages in dMMR (e) or pMMR patients (f). \* *P*\<0.05, N.S, not significant.](jcav10p1745g003){#F3}

![The different association of circulating lymphocyte level and prognosis between dMMR and pMMR CRC patients. (a-b). Kaplan-Meier survival curves comparing the overall survival of the level of circulating lymphocytes in dMMR (a) or pMMR CRC patients (b). (c-d) Kaplan-Meier survival curves comparing the disease-free survival of the level of circulating lymphocytes in dMMR (c) or pMMR CRC patients (d). Group comparison (Disease-free survival: \< 3 year, n=92 vs \> 3 year, n=76) combined the level of lymphocytes and different disease-free survival in dMMR (e). Group comparison (Disease-free survival: \< 3 year, n=154 vs \> 3 year, n=15) combined the level of lymphocytes and different disease-free survival in pMMR patients (f). \* *P*\< 0.05, N.S, not significant.](jcav10p1745g004){#F4}

![Localized PD-L1 expression is associated with CRC patient survival. (a-c). Kaplan-Meier survival curves comparing the overall survival of the level of tumor PD-L1 (a), stroma PD-L1 (b), or TIL PD-L1 (c) expression in CRC patients. (d-f). Kaplan-Meier survival curves comparing the disease-free survival of the level of tumor PD-L1(d), stroma PD-L1 (e), or TIL PD-L1 (f) expression in CRC patients.](jcav10p1745g005){#F5}

###### 

Comparison of clinicopathological characteristics between dMMR and pMMR CRC patients.

                                dMMR   pMMR                   
  ----------------------------- ------ ------ ----- --------- ---------
  **Age (years)**                                             \<0.001
  Mean                          53.5   58.5                   
  SD                            12.5   11.7                   
  **Gender**                                                  0.219
  Male                          109    64.9   98    58.0      
  Female                        59     35.1   71    42.0      
  **Tumor location**                                          0.001
  Right hemicolon               78     46.4   47    27.8      
  Left hemicolon                54     32.1   83    49.1      
  Rectum                        36     21.4   39    23.1      
  **Tumor grade**                                             \<0.001
  1                             1      0.6    2     1.2       
  2                             89     53.0   123   72.8      
  3                             78     46.4   44    26.0      
  **Histological subtype**                          \<0.001   
  Mucinous                      60     35.7   30    17.8      
  Other                         108    64.3   139   82.2      
  **Tumor stage**                                             0.003
  T~1~                          5      3.0    8     4.7       
  T~2~                          24     14.3   25    14.8      
  T~3~                          96     57.1   120   71.0      
  T~4a~                         30     17.9   11    6.5       
  T~4b~                         13     7.7    5     3.0       
  **Regional LNs metastasis**                       0.155     
  N~0~                          122    72.6   121   71.6      
  N~1~                          37     22.0   30    17.8      
  N~2~                          9      5.4    18    10.7      
  **Distant metastasis**                            0.653     
  M~0~                          157    93.5   160   94.7      
  M~1~                          11     6.5    9     5.3       
  **AJCC stage**                                              0.971
  1                             26     15.5   27    16.0      
  2                             89     53.0   91    53.8      
  3                             42     25.0   42    24.9      
  4                             11     6.5    9     5.3       
  **Perineural invasion**                           0.129     
  Negative                      153    91.1   144   85.2      
  Positive                      15     8.9    25    14.8      
  **Vascular invasion**                             0.080     
  Negative                      155    92.3   145   85.8      
  Positive                      13     7.7    24    14.2      
  **Number of retrieved LNs**                       0.304     
  \<12                          54     33.3   66    39.1      
  ≥12                           108    66.7   103   60.9      
  **Chemotherapy**                                            0.304
  Yes                           69     33.3   97    39.1      
  No                            99     66.7   72    60.9      
  **Radiotherapy**                                            0.368
  Yes                           12     7.1    8     4.7       
  No                            156    92.9   161   95.3      

###### 

Comparison of tumor markers and systemic inflammatory status between dMMR and pMMR CRC patients.

                                  dMMR   pMMR                   
  ------------------------------- ------ ------ ----- --------- -------
  **CEA (μg/ml)**                                               0.046
  ≥5.0                            59     35.1   78    46.2      
  \<5.0                           109    64.9   91    53.8      
  **CA19-9 (units/ml)**                               0.790     
  ≥30                             36     21.4   34    20.1      
  \<30                            132    78.6   135   79.9      
  **Albumin (g/l)**                                             0.464
  ≥35                             154    91.7   150   88.8      
  \<35                            14     8.3    19    11.2      
  **C-reactive protein (mg/l)**                       \<0.001   
  ≥8.2                            65     38.7   29    17.2      
  \<8.2                           103    61.3   140   82.8      
  **Neutrophil (×10^9^/l)**                           0.248     
  \<2.0                           5      3.0    8     5.0       
  2.0-7.0                         145    86.3   141   88.7      
  \>7.0                           18     10.7   10    8.6       
  **Lymphocyte (×10^9^/l)**                           1.000     
  ≥1.12                           162    96.4   163   96.4      
  \<1.12                          6      3.6    6     3.6       
  **CAR (mg/g)**                                                0.056
  ≥0.03                           136    81.0   123   71.9      
  \<0.03                          32     19.0   48    28.1      
  **NLR**                                                       0.017
  ≥1.8                            135    80.4   116   68.6      
  \<1.8                           33     19.6   53    31.4      
  **GPS**                                                       0.001
  0                               103    61.3   133   78.7      
  1                               51     30.4   24    14.2      
  2                               14     8.3    12    7.1       

###### 

Comparison of PD-1/PD-L1 expression pattern between dMMR and pMMR CRC patients.

                            dMMR   pMMR                 
  ------------------------- ------ ------ ----- ------- ---------
  **TIL Numbers (/5HPF)**                       0.011   
  Mean                      63.4   22.6                 
  SD                        58.6   18.4                 
  **PD-1 (Total)**                                      0.504
  Positive                  105    62.5   99    58.6    
  Negative                  63     37.5   70    41.4    
  **PD-1 (Tumor)**                                      1.000
  Positive                  38     22.6   38    22.5    
  Negative                  130    77.4   131   77.5    
  **PD-1 (TIL)**                                        0.039
  Positive                  92     54.8   73    43.2    
  Negative                  76     45.2   96    56.8    
  **PD-1 (Stroma)**                                     0.718
  Positive                  49     29.2   46    27.2    
  Negative                  119    70.8   123   72.8    
  **PD-L1 (Total)**                                     0.231
  Positive                  93     55.4   82    48.5    
  Negative                  75     44.6   87    51.5    
  **PD-L1 (Tumor)**                                     0.790
  Positive                  36     21.4   34    20.1    
  Negative                  132    78.6   135   79.9    
  **PD-L1 ((TIL)**                                      0.446
  Positive                  82     48.8   90    53.3    
  Negative                  86     51.2   79    46.7    
  **PD-L1 (Stroma)**                                    \<0.001
  Positive                  37     22.0   74    43.8    
  Negative                  131    78.0   95    56.2    

###### 

Univariate and Multivariate analyses of prognostic factors for overall survival of CRC patients.

                                Univariate analysis   Multivariate analysis                                    
  ----------------------------- --------------------- ----------------------- --------- ------ --------------- -------
  Regional LNs metastasis ≥N1   3.86                  (1.65,9.03)             0.002     1.18   (0.28, 4.91)    0.824
  Distant metastasis            15.09                 (6.53, 34.86)           \<0.001   5.23   (1.54, 17.83)   0.008
  AJCC stage ≥3                 14.93                 (4.42, 50.48)           \<0.001   7.35   (1.01, 53.69)   0.049
  Vascular invasion             6.55                  (2.54, 16.86)           \<0.001   4.98   (1.63, 15.24)   0.005
  Chemotherapy                  4.06                  (1.48, 11.11)           0.006     1.68   (0.51, 5.55)    0.394
  Radiotherapy                  6.62                  (2.69, 16.30)           \<0.001   4.40   (1.49,12.93)    0.006
  CA19-9 (≥30 units/ml)         2.49                  (1.05, 5.95)            0.040     2.02   (0.69, 5.91)    0.198
  Lymphocyte (≥1.12×10^9^/l)    4.45                  (1.32, 15.06)           0.016     4.82   (1.12, 20.69)   0.035
  TIL Numbers (\>40)            0.44                  (0.19, 1.03)            0.058     \-     \-              \-
  PD-L1 expression (Total)      0.40                  (0.17, 0.93)            0.033     0.46   (0.12,1.77)     0.257
  PD-L1 expression (TIL)        0.69                  (0.49,0.96)             0.026     0.66   (0.21, 2.05)    0.469

###### 

Univariate and Multivariate analyses of prognostic factors for disease-free survival of CRC patients.

                                 Univariate analysis   Multivariate analysis                                    
  ------------------------------ --------------------- ----------------------- --------- ------ --------------- ---------
  Regional LNs metastasis ≥N1    3.67                  (2.09, 6.47)            \<0.001   1.96   (0.58, 6.61)    0.278
  Distant metastasis             8.25                  (4.36, 15.60)           \<0.001   4.39   (1.58, 12.21)   0.005
  AJCC stage ≥3                  5.63                  (3.07, 10.34)           \<0.001   1.89   (0.47, 7.57)    0.368
  Vascular invasion              2.70                  (1.34, 5.44)            0.005     1.77   (0.83, 3.76)    0.139
  Number of retrieved LNs \<12   2.43                  (1.39, 4.25)            0.002     2.01   (1.00, 4.03)    0.049
  Chemotherapy                   3.27                  (1.73, 6.19)            \<0.001   1.23   (0.58, 2.59)    0.593
  Radiotherapy                   8.56                  (4.58, 15.99)           \<0.001   6.80   (2.86, 16.17)   \<0.001
  CEA (≥5 μg/ml)                 1.38                  (1.03, 1.85)            0.029     0.82   (0.55, 1.22)    0.329
  CA19-9 (≥30 units/ml)          2.06                  (1.12, 3.79)            0.020     1.35   (0.96, 1.89)    0.081
  Lymphocyte (≥1.12×10^9^/l)     1.32                  (1.07, 1.61)            0.008     0.87   (0.66, 1.15)    0.320
  TIL Numbers (\>40)             0.86                  (0.31, 2.28)            0.346     \-     \-              \-
  PD-L1 expression (Total)       0.40                  (0.17, 0.93)            0.033     1.09   (0.84, 1.41)    0.513
  PD-L1 expression (TIL)         0.51                  (0.28,0.92)             0.025     0.98   (0.75, 1.28)    0.863
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